Abstract Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the…
Keyword: treatment
Cannabidiol for the treatment of psychosis in Parkinson’s disease
The management of psychosis in Parkinson’s disease (PD) has been considered a great challenge for clinicians and there is a need for new pharmacological intervention. Previously an antipsychotic and neuroprotective…
Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases?
Since the discovery of the cannabinoid receptors and their endogenous ligands, significant advances have been made in studying the physiological function of the endocannabinoid system. The presence of cannabinoid receptors…
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
Introduction: Parkinson’s disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid…
PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program
Background: New Mexico was the first state to list post-traumatic stress disorder (PTSD) as a condition for the use of medical cannabis. There are no published studies, other than case…
Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence
Drug addiction is a chronically relapsing disorder characterized by the compulsive desire to use drugs and a loss of control over consumption. Cannabidiol (CBD), the second most abundant component of…